Glenmark Pharma

{
  "main_header": {
    "sid": 780863,
    "name": "Glenmark Pharma",
    "stock_name": "Glenmark Pharma",
    "full_name": "Glenmark Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/glenmark-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,155.60",
    "chg": -17.6,
    "chgp": "-0.81%",
    "dir": -1,
    "prev_price": "2,173.20",
    "mcapval": "61,153.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532296,
    "symbol": "GLENMARK",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE935A01035",
    "curr_date": "Jun 15, 03:30 PM",
    "curr_time": "08:16 AM",
    "last_traded_at": "Jun 15, 03:30 PM IST",
    "bse_nse_vol": "6.56 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 15, 2026",
    "traded_date_str": "2026 06 15",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "SM",
      "url": "https://www.marketsmojo.com/mojopro/stock-of-the-month",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-0&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Glenmark Pharmaceuticals Declines 4.78%: 4 Key Factors Behind the Weekly Slide",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-declines-478-4-key-factors-behind-the-weekly-slide-4052232",
        "imagepath": "",
        "date": "2026-06-13 17:09:56",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>1 June:</strong> Surge in put option activity signals bearish positioning</p>\n                    <p><strong>2 June:</strong> Q4 FY26 results reveal sequential decline despite strong quarter</p>\n                    <p><strong>2 June:</strong> Technical momentum shifts to mildly bullish with mixed indicators</p>\n                    <p><strong>2 June:</strong> Valuation shifts from very attractive to attractive amid market volatility</p>\n                    <p><strong>5 June:</strong> Week closes at ₹2,165.50, down 0.73% on the day</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><di..."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. is Rated Buy",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glenmark-pharmaceuticals-ltd-is-rated-buy-4046466",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GlenmarkPharmac_mojoScore_4046466.png",
        "date": "2026-06-11 10:10:40",
        "description": "Glenmark Pharmaceuticals Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 01 June 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 11 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook."
      },
      {
        "title": "Are Glenmark Pharmaceuticals Ltd. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-glenmark-pharmaceuticals-ltd-latest-results-good-or-bad-4034991",
        "imagepath": "",
        "date": "2026-06-03 19:13:28",
        "description": "Glenmark Pharmaceuticals Ltd. reported its financial results for the quarter ending March 2026, revealing a mixed performance. The company's net sales for this quarter stood at ₹3,770.59 crores, reflecting a sequential decline of 3.33% from the previous quarter, although this figure represents a year-on-year increase of 15.80%. The net profit for the same period was ₹301.41 crores, which indicates a sequential decrease of 25.25%, but a substantial year-on-year growth of 6,381.94% from a very low base in the previous year.\n\nThe operating margin for Q4 FY26 contracted to 20.28%, down from 22.37% in the prior quarter, which is attributed to the unwinding of exceptional profitability seen in Q3 FY26 and rising employee costs. Despite this sequential moderation, the operating margin remains significantly higher than the 17.42% recorded in Q4 FY25, suggesting ongoing operational improvements on an annual basis.\n\n..."
      },
      {
        "title": "Glenmark Pharmaceuticals Q4 FY26: Exceptional Quarter Marred by Sequential Decline",
        "link": "https://www.marketsmojo.com/news/result-analysis/glenmark-pharmaceuticals-q4-fy26-exceptional-quarter-marred-by-sequential-decline-4032396",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GlenmarkPharmac_quaterlyResult_4032396.png",
        "date": "2026-06-02 18:14:43",
        "description": "Glenmark Pharmaceuticals Ltd., a prominent player in India's pharmaceutical and biotechnology sector with a market capitalisation of ₹61,576 crores, delivered a mixed performance in Q4 FY26 (January-March 2026), reporting a consolidated net profit of ₹301.41 crores. Whilst the company demonstrated robust year-on-year growth of 6,381.94% from an exceptionally low base in Q4 FY25, the quarter witnessed a sequential decline of 25.25% from Q3 FY26's strong showing of ₹403.21 crores. The stock has reacted cautiously, trading at ₹2,184.90 as of June 2, 2026, down 0.74% from the previous close, reflecting investor concerns about the sequential moderation despite impressive annual comparisons."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-4029616",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GlenmarkPharmac_technicaldot_4029616.png",
        "date": "2026-06-02 08:06:40",
        "description": "Glenmark Pharmaceuticals Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a day decline of 3.21% to close at ₹2,201.20, the stock’s broader technical indicators reveal a complex interplay of signals that investors should carefully analyse."
      },
      {
        "title": "Glenmark Pharmaceuticals Valuation Shifts to Attractive Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-valuation-shifts-to-attractive-amid-market-volatility-4029340",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GlenmarkPharmac_valuationdot_4029340.png",
        "date": "2026-06-02 08:03:30",
        "description": "Glenmark Pharmaceuticals Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. Despite a recent dip in share price, the company’s fundamental metrics and relative valuation against peers suggest a compelling investment case for mid-cap investors seeking exposure in the pharmaceutical space."
      },
      {
        "title": "Why is Glenmark Pharmaceuticals Ltd. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-glenmark-pharmaceuticals-ltd-fallingrising-4028862",
        "imagepath": "",
        "date": "2026-06-02 02:07:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Price Movement and Market Performance</strong></p>\n<p>The stock has been under pressure in recent sessions, registering a consecutive two-day decline that has resulted in a cumulative loss of 7.48%. On the day in question, Glenmark’s share price touched an intraday low of ₹2,180, representing a 4.14% dip from previous levels. This underperformance is further highlighted by the stock lagging its sector by 2.42% on the same day. The weighted average price indicates that a significant volume of shares traded closer to the day’s low, signalling selling pressure among investors.</p>\n<p>From a technical perspective, the stock is trading above its 100-day and 200-day moving averages, which typically suggests a positive long-term trend. However, it remains below its 5-day, 20-day, and 50-..."
      },
      {
        "title": "Rs 2,200 Puts — Just Below Current Price — Draw 1,971 Contracts on Glenmark Pharmaceuticals Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-surge-in-put-option-activity-amid-bearish-sentiment-4025980",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GlenmarkPharmac_most_active_stocks_puts_4025980.png",
        "date": "2026-06-01 10:00:13",
        "description": "Rs 2,200 put options on Glenmark Pharmaceuticals Ltd. attracted significant attention on 1 June 2026, with 1,971 contracts traded against an underlying price of Rs 2,197.10. This strike sits marginally out-of-the-money, raising questions about whether the activity signals protective hedging or a directional bearish stance."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. is Rated Strong Buy",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glenmark-pharmaceuticals-ltd-is-rated-strong-buy-4024277",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/GlenmarkPharmac_mojoScore_4024277.png",
        "date": "2026-05-31 10:10:42",
        "description": "Glenmark Pharmaceuticals Ltd. is rated 'Strong Buy' by MarketsMOJO, with this rating last updated on 19 May 2026. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the company’s current position as of 31 May 2026, providing investors with the most up-to-date insight into the stock’s performance and outlook."
      }
    ],
    "total": 565,
    "sid": "780863",
    "stock_news_url": "https://www.marketsmojo.com/news/glenmark-pharmaceuticals-780863"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "11-Jun-2026",
      "details": "Glenmark launches Winlevi (clascoterone) 10 mg/g cream in Key European Markets for the Treatment of Acne Vulgaris",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "09-Jun-2026",
      "details": "Please find attached Investor Presentation to be made at Glenmark Pharmaceuticals Limited Investor Day 2026 today.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "05-Jun-2026",
      "details": "Glenmark Pharmaceuticals Inc. USA launches Lacosamide Injection USP 200 mg/ 20mL (10 mg/mL) Single-Dose Vials",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has declared <strong>250%</strong> dividend, ex-date: 03 Oct 25",
          "dt": "2025-10-03",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has announced <strong>1:2</strong> stock split, ex-date: 10 Sep 07",
          "dt": "2007-09-10",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Glenmark Pharmaceuticals Declines 4.78%: 4 Key Factors Behind the Weekly Slide

2026-06-13 17:09:56

Key Events This Week

1 June: Surge in put option activity signals bearish positioning

2 June: Q4 FY26 results reveal sequential decline despite strong quarter

2 June: Technical momentum shifts to mildly bullish with mixed indicators

2 June: Valuation shifts from very attractive to attractive amid market volatility

5 June: Week closes at ₹2,165.50, down 0.73% on the day

Week Open

Read full news article

Glenmark Pharmaceuticals Ltd. is Rated Buy

2026-06-11 10:10:40

Glenmark Pharmaceuticals Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 01 June 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 11 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook.

Read full news article

Are Glenmark Pharmaceuticals Ltd. latest results good or bad?

2026-06-03 19:13:28

Glenmark Pharmaceuticals Ltd. reported its financial results for the quarter ending March 2026, revealing a mixed performance. The company's net sales for this quarter stood at ₹3,770.59 crores, reflecting a sequential decline of 3.33% from the previous quarter, although this figure represents a year-on-year increase of 15.80%. The net profit for the same period was ₹301.41 crores, which indicates a sequential decrease of 25.25%, but a substantial year-on-year growth of 6,381.94% from a very low base in the previous year. The operating margin for Q4 FY26 contracted to 20.28%, down from 22.37% in the prior quarter, which is attributed to the unwinding of exceptional profitability seen in Q3 FY26 and rising employee costs. Despite this sequential moderation, the operating margin remains significantly higher than the 17.42% recorded in Q4 FY25, suggesting ongoing operational improvements on an annual basis. ...

Read full news article

Glenmark Pharmaceuticals Q4 FY26: Exceptional Quarter Marred by Sequential Decline

2026-06-02 18:14:43

Glenmark Pharmaceuticals Ltd., a prominent player in India's pharmaceutical and biotechnology sector with a market capitalisation of ₹61,576 crores, delivered a mixed performance in Q4 FY26 (January-March 2026), reporting a consolidated net profit of ₹301.41 crores. Whilst the company demonstrated robust year-on-year growth of 6,381.94% from an exceptionally low base in Q4 FY25, the quarter witnessed a sequential decline of 25.25% from Q3 FY26's strong showing of ₹403.21 crores. The stock has reacted cautiously, trading at ₹2,184.90 as of June 2, 2026, down 0.74% from the previous close, reflecting investor concerns about the sequential moderation despite impressive annual comparisons.

Read full news article

Glenmark Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals

2026-06-02 08:06:40

Glenmark Pharmaceuticals Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a day decline of 3.21% to close at ₹2,201.20, the stock’s broader technical indicators reveal a complex interplay of signals that investors should carefully analyse.

Read full news article

Glenmark Pharmaceuticals Valuation Shifts to Attractive Amid Market Volatility

2026-06-02 08:03:30

Glenmark Pharmaceuticals Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. Despite a recent dip in share price, the company’s fundamental metrics and relative valuation against peers suggest a compelling investment case for mid-cap investors seeking exposure in the pharmaceutical space.

Read full news article

Why is Glenmark Pharmaceuticals Ltd. falling/rising?

2026-06-02 02:07:05

Short-Term Price Movement and Market Performance

The stock has been under pressure in recent sessions, registering a consecutive two-day decline that has resulted in a cumulative loss of 7.48%. On the day in question, Glenmark’s share price touched an intraday low of ₹2,180, representing a 4.14% dip from previous levels. This underperformance is further highlighted by the stock lagging its sector by 2.42% on the same day. The weighted average price indicates that a significant volume of shares traded closer to the day’s low, signalling selling pressure among investors.

From a technical perspective, the stock is trading above its 100-day and 200-day moving averages, which typically suggests a positive long-term trend. However, it remains below its 5-day, 20-day, and 50-...

Read full news article

Rs 2,200 Puts — Just Below Current Price — Draw 1,971 Contracts on Glenmark Pharmaceuticals Ltd.

2026-06-01 10:00:13

Rs 2,200 put options on Glenmark Pharmaceuticals Ltd. attracted significant attention on 1 June 2026, with 1,971 contracts traded against an underlying price of Rs 2,197.10. This strike sits marginally out-of-the-money, raising questions about whether the activity signals protective hedging or a directional bearish stance.

Read full news article

Glenmark Pharmaceuticals Ltd. is Rated Strong Buy

2026-05-31 10:10:42

Glenmark Pharmaceuticals Ltd. is rated 'Strong Buy' by MarketsMOJO, with this rating last updated on 19 May 2026. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the company’s current position as of 31 May 2026, providing investors with the most up-to-date insight into the stock’s performance and outlook.

Read full news article

View All News